NASDAQ$PROK
ProKidney Corp · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
ProKidney LP's financial results for Q2 2022 were announced, along with a business update, highlighting the completion of a business combination with Social Capital Suvretta Holdings, III.
ProKidney reported its financial results for the second quarter ended June 30, 2022. The company completed its business combination with Social Capital Suvretta Holdings, III, receiving gross proceeds of $596.5 million. Research and development expenses were $11.6 million, while general and administrative expenses were $9.2 million. The company's cash and cash equivalents totaled $21.9 million as of June 30, 2022.
- Completed business combination with Social Capital Suvretta Holdings, III.
- Received gross proceeds of $596.5 million from the business combination.
- Continued enrollment in the U.S. Phase 3 study (REGEN-006) to assess the efficacy of REACT™ injections.
- Expanded target enrollment for REGEN-007 from 30 subjects to up to 50 subjects.
Headline financials
Revenue & EPS history
ProKidney · Revenue · Quarterly
$338K
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 15 quarterly earnings reports · overlaid with Q2 2022
-2.4%
Avg return
Earnings day
-3.0%
Avg return
5 days after
+2.6%
Avg return
30 days after
25%
4 / 16 earnings
Positive
+18.0%
Q1 2024
Best reaction
-13.1%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.3% | -1.2% | -4.7% | |
| Q4 2025 | -4.0% | -8.9% | +2.3% | |
| Q3 2025 | -8.8% | -16.6% | -24.9% | |
| Q2 2025 | -0.9% | +4.7% | +32.2% | |
| Q1 2025 | -6.0% | -9.3% | -1.4% | |
| Q4 2024 | -6.8% | -7.7% | -23.9% | |
| Q3 2024 | -3.7% | -21.2% | -12.6% | |
| Q2 2024 | -0.5% | +9.1% | +11.5% | |
| Q1 2024 | +18.0% | +50.2% | +22.2% | |
| Q4 2023 | -4.1% | +8.9% | +39.7% | |
| Q3 2023 | -13.1% | -24.4% | +20.0% | |
| Q2 2023 | +0.4% | -14.5% | -37.5% | |
| Q1 2023 | +1.2% | +8.1% | +34.0% | |
| Q4 2022 | -9.8% | -12.9% | -24.6% | |
| Q3 2022 | -4.7% | -14.8% | -23.6% | |
| Q2 2022 | +7.3% | +2.7% | +32.6% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro